Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
Want to see SNOA full AI Analyst Report?
SNOA Stock Chart & Stats
$3.78
-$0.06(-2.19%)
At close: 4:00 PM EST
$3.78
-$0.06(-2.19%)
Day’s Range― - ―
52-Week Range$0.85 - $6.92
Previous CloseN/A
Volume16.09K
Average Volume (3M)65.28K
Market Cap
$3.79M
Enterprise Value$66.66K
Total Cash (Recent Filing)$2.56M
Total Debt (Recent Filing)$655.00K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding3,473,554
10 Day Avg. Volume126,678
30 Day Avg. Volume65,281
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.62
Price to Sales (P/S)0.19
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$23.91M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow reported leverage (debt-to-equity ~0.14) reduces near-term solvency risk and gives management financial flexibility. With limited debt service obligations, Sonoma can prioritize commercial investment or absorb continued losses without immediate refinancing pressure, supporting operational resilience over the next several months.
Kenvue Supply AgreementThe multi-year Microcyn® manufacturing and supply agreement with Kenvue provides a durable commercial channel into the U.S. market. A defined term and renewal options deliver predictable demand and distribution reach, increasing planning visibility and the potential to scale volumes and improve unit economics over a multi-month to multi-year horizon.
Revenue Resilience & MarginsConsistent top-line growth and steady gross margins (~37–38%) indicate persistent demand for HOCl products and sustainable unit economics. This revenue resilience provides a base for operating leverage if sales scale further, making a future profitability inflection more achievable without relying solely on cost cuts.
Bears Say
Negative Cash FlowTrailing-twelve-month OCF and FCF remain materially negative, reflecting ongoing cash burn. Persistent negative cash generation constrains Sonoma's ability to fund commercialization, R&D, or working capital from operations, forcing reliance on external financing and creating execution risk if capital access tightens over the coming months.
Persistent UnprofitabilityDeep negative net margins and very poor returns on equity signal structural profitability issues. Continued losses erode equity and limit internal reinvestment capacity, meaning Sonoma must materially grow revenue or materially improve cost structure to achieve durable profitability and restore capital efficiency over a 2–6 month horizon.
Reliance On External FundingThe recent equity offering to raise roughly $3.5M underscores reliance on capital markets to sustain operations. Regularly tapping external financing is a structural vulnerability: it dilutes shareholders, depends on market access, and highlights that cash generation from operations remains insufficient for medium-term funding needs.
Sonoma Pharmaceuticals News
SNOA FAQ
What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $0.85 and its highest was $6.92 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Sonoma Pharmaceuticals’s market cap is $3.79M.
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
Sonoma Pharmaceuticals’s upcoming earnings report date is Jul 15, 2026 which is in 31 days.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Feb 10, 2026. The company reported -$0.352 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.062.
Is Sonoma Pharmaceuticals overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 3,473,554 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of -$0.352 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went up 1.423%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Currently, no hedge funds are holding shares in SNOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Technical Analysis
China Pharma Holdings
―
―
RedHill Biopharma
―
Sunshine Biopharma
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
14.62%
Insiders
0.97% Mutual Funds
0.67% Other Institutional Investors
83.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---